the australian - starpharma, page-5

l wish the company would be more open with their news flow. There's rarely any specifics but rather generalisations. We discover more from reading this article (not that it was much) than was disclosed to the asx and ultimately to shareholders. Questions answered like "when do we expect cash flows from product sales" would be handy. What about the agro chemical side. All we know is that their dendrimers added to round up increases the leaf burn rate. Are monsanto excited about this and what does this mean in terms of making money for the shareholders?

Also the switch to Ansell appears to have delayed commecialising by maybe a year. Why a year? And what about the other applications. Where are they headed towards optimising shareholder value with their water treatment program for example. With the BV program l concede trials are in place and there is newsflow but again an estimated timeframe would be handy.

Think its about time some of us shareholders started to quiz the company about these types of things. l'm very keen on SPL and their technology but a time comes after holding for year upon year upon year when one needs more specifics instead of all this fluffy stuff. Maybe l'm just having a bad day.

l'm keen to know what others in this forum think.